Botanix Q1 FY27 slides: prescriptions rise, revenue stalls on PA issues

Botanix Pharmaceuticals reported a flat Q1 FY27 revenue of $10.1 million, despite a 32% increase in prescription volume for its hyperhidrosis treatment Sofdra. The company's shares dropped 3.85%, trading at $0.013, near the bottom of its 52-week range. Botanix's Q1 FY27 cash position stood at $24.4 million, down from $36.6 million in the prior quarter, as the company faces significant cash burn and challenges in translating prescription growth into revenue.

The prescription growth in Q1 FY27 was steady, with 35,130 prescriptions shipped compared to 33,358 in Q4 FY26. Gross-to-net yield declined to 21% from 22% in the prior quarter, primarily due to lower prior authorization submission volumes. Botanix outlined an aggressive restructuring plan, targeting a 60% headcount reduction and 50% operating expenditure reduction for the remainder of FY27, while aiming to preserve roughly 75% of revenue-generating capacity.

The restructuring aims to extend the financial runway and address operational inefficiencies, primarily in prior authorization processing.